POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination
PR Newswire•09/10/2026•16:05 ET
1
Key Highlights
- ➤Nasdaq determination subjects POM securities to delisting from The Nasdaq Global Market
- ➤ADS closing bid price stayed below $1 for 30 consecutive business days
- ➤1-for-18 reverse split makes POM ineligible for standard 180-day compliance period
- ➤POM plans to appeal by October 13, staying suspension and Form 25-NSE filing
- ➤Without timely appeal, trading suspension begins October 15, 2026
POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination PR Newswire
GUANGZHOU, China, Oct. 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that it received a staff determination letter (the "Letter") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") on October 6, 2026.
Get started
Create a free account to read the full story.